News Related to Allogene Therapeutics

Related coverage linked through entity extraction aliases.

Allogene to present ALPHA3 interim futility analysis for cema-cel in first-line LBCL on April 13

Apr 11, 2026

Allogene Therapeutics said it will present interim futility analysis data from the Phase 2 ALPHA3 trial of cema-cel in first-line consolidation LBCL on April 13, 2026. The readout will assess day-45 MRD clearance in 12 patients per arm randomized to cema-cel or observation.

Cardiovascular Biologics and Cell Therapy Markets Project Strong Growth Through 2033

Mar 05, 2026

The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.